High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: Effects of antihypertensive treatment

Journal of Vascular Research

Volumn 36, Issue 5, 1999, Pages 393-403

  Rizzoni, Damiano ^a   Porteri, Enzo ^b   Piccoli, Alfonso ^b   Castellano, Maurizio ^b   Pasini, Giancarlo ^b   Guelfi, Daniele ^b   Muiesan, Maria Lorenza ^b   Rosei, Enrico Agabiti ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b NONE

Author keywords

Candesartan; Enalapril; Endothelin; Endothelium; Insulin; Norepinephrine; Spontaneously hypertensive rats

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; INSULIN; NORADRENALIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; HYPERTENSION; MESENTERIC ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; SPONTANEOUSLY HYPERTENSIVE RAT; VASOCONSTRICTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENALAPRIL; HYPERTENSION; INSULIN; MESENTERIC ARTERIES; NOREPINEPHRINE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ANGIOTENSIN; SYSTOLE; TETRAZOLES; VASOCONSTRICTOR AGENTS;

EID: 0032717746     PISSN: 10181172     EISSN: None     Source Type: Journal    
DOI: 10.1159/000025679     Document Type: Article

References (47)

1. Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595-1607.
2. Reaven GM: Insulin resistance, hyperinsulinemia and hypertriglyceridemia in the etiology and the clinical course of hypertension. Am J Med 1991;90:7S-12S.
3. Baron AD, Brechtel-Hook G, Johnson A, Hardin D: Skeletal muscle blood flow: A possible link between insulin resistance and blood pressure. Hypertension 1993;21:129-135.
4. Bhanot S, McNeill JH: Insulin and hypertension: A causal relationship? Cardiovasc Res 1996;31:212-221.
5. Sowers JR: Insulin and insulin-like growth factor in normal and pathological cardiovascular physiology. Hypertension 1997;29:691-699.
6. Lembo G, Iaccarino G, Vecchione C, Rendina V, Trimarco B: Insulin modulation of vascular reactivity is already impaired in prehypertensive spontaneously hypertensive rats. Hypertension 1995;26:290-293.
7. Wambach GK, Liu D: Insulin attenuates vasoconstriction induced by noradrenaline, serotonin and potassium chloride in rat mesenteric resistance arteries. J Hypertens 1991;9 (suppl 6):S198-S199.
8. Townsend RR, Yamamoto R, Nickols M, DiPette DJ, Nickols GA: Insulin enhances pressor responses to norepinephrine in rat mesenteric vasculature. Hypertension 1992;19(suppl II): II-105-II-110.
9. Wu H, Jeng YY, Yue C, Chyu KY, Hsueh WA, Chan TM: Endothelial-dependent vascular effects of insulin and insulin-like growth factor I in the perfused rat mesenteric artery and aortic ring. Diabetes 1994;43:1027-1032.
10. Sung BH, Wilson MF, Izzo JL, Ramirez L, Dandona P: Moserately obese, insulin-resistant women exhibit abnormal vascular reactivity to stress. Hypertension 1997;30:848-853.
11. Taddei S, Virdis A, Mattei P, Natali A, Ferrannini E, Salvetti A: Effect of insulin on acetylcholine-induces vasodilatation in normotensive subjects and in patients with essential hypertension. Circulation 1995;92:2911-2918.
12. 2-adrenergic vasorelaxation by a pertussis toxin mechanism. Hypertension 1997;30:1128-1134.
13. Creager MA, Liang CS, Coffman JD: Beta adrenergic-mediated vasodilator response to insulin in the human forearm. J Pharmacol Exp Ther 1985;235:709-714.
14. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL: Hyperinsulinemia produces both sympathetic neural activation and vasodilatation in normal humans. J Clin Invest 1991; 87:2246-2252.
15. Hausberg M, Mark AL, Hoffman RP, Sinkey CA, Anderson EA: Dissociation of sympathoexcitatory and vasodilator actions of modestly elevated plasma insulin levels. J Hypertens 1985;13:1015-1021.
16. Anderson EA, Mark AL: The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 1993;21:136-141.
17. Lembo G, Rendina V, Iaccarino G, Lamenza F, Volpe M, Trimarco B: Insulin reduces reflex forearm sympathetic vasoconstriction in healthy humans. Hypertension 1993;21:1015-1019.
18. Shimosawa T, Ando K, Fujita T: Effect of insulin on norepinephrine overflow at peripheral sympathetic nerve endings in young spontaneously hypertensive rats. Am J Hypertens 1996;9:1119-1125.
19. Lembo G, Rendina V, Iaccarino G, Lamenza F, Volpe M, Trimarco B: Insulin does not modulate reflex forearm sympathetic vasoconstriction in patients with essential hypertension. J Hypertens 1993;11(suppl 5):S272-S273.
20. Morimoto S, Ogihara T. TCV-116, a new angiotensin II type-1 receptor antagonist. Cardiovasc Drug Rev 1994;12:153-164.
21. Mulvany MJ, Halpern W: Contractile properties of small resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;42:19-26.
22. Mulvany MJ, Hansen PK, Aalkjaer C: Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ Res 1978;43: 854-864.
23. Stasch JP, Hirth-Dietrich C, Frobel K, Wegener M: Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1995;8:1128-1134.
24. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti Rosei E: Delayed development of hypertension after short-term nitrendipine treatment. Hypertension 1994;24: 131-139.
25. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Cinelli A, Agabiti Rosei E: Effects of low and high doses of fosinopril on the structure and function of resistance arteries. Hypertension 1995;26:118-123.
26. Rizzoni D, Castellano M, Porteri E, Bettoni G, Muiesan ML, Agabiti-Rosei E: Vascular structural and functional alterations before and after the development of hypertension in SHR. Am J Hypertens 1994;7:193-200.
27. Castellano D, Rizzoni D, Beschi M, Böhm M, Porteri E, Bettoni G, Cinelli A, Agabiti Rosei E: Chronic ACE-inhibitor treatment and adrenergic mechanisms in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995; 26:381-387.
28. Ferri C, Pittoni V, Piccoli A, Laurenti O, Cassone MR, Bellini C, Properzi G, Valesini G, De Mattia G, Santucci A: Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo. J Clin Endocrinol Metab 1995;80:829-835.
29. Nava P, Collados M, Masso F, Guarner V: Endothelin mediation of insulin and glucose-induced changes in vascular contractility. Hypertension 1997;30:825-829.
30. Zerrouk A, Champeroux P, Safar M, Brisac AM: Role of endothelium in the endothelin-1-mediated potentiation of the norepinephrine response in the aorta of hypertensive rats. J Hypertens 1997;15:1101-1111.
31. Yang Z, Richard V, Von Segesser L, Bauer E, Stulz P, Turina M: Threshold concentrations of endothelin-1 potentiates contractions to norepinephrine and serotonin in human arteries: A new mechanism of vasospasm. Circulation 1990;82:188-195.
32. Tabuchi Y, Nakamaru M, Rakugi H, Nagano M, Higashimori K, Mikami H: Effects of endothelin on neuroeffector junctions in mesenteric arteries of hypertensive rats. Hypertension 1990;15:739-743.
33. Reid JJ, Vo PA, Lieu AT, Wong-Dusting HK, Rand MJ: Modulation of norepinephrine-induced vasoconstriction by endothelin-1 and nitric oxide in rat tail artery. J Cardiovasc Pharmacol 1991;17(suppl 7):S272-S275.
34. Henrion D, Laher I: Potentiation of norepinephrine-induced contractions by endothelin-1 in the rabbit aorta. Hypertension 1993;22:78-83.
35. Dohi Y, Hahn AWA, Boulanger CM, Bühler FR, Lüscher TF: Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 1992;9:131-137.
36. James GM, Hodgson WC: Potentiation by endothelin-1 of 5-hydroxytryptamine responses in aortae from streptozotocin-diabetic rats: A role for thromboxane A2. Br J Pharmacol 1995;114:1236-1240.
37. Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A: Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997;29(1 pt 2):274-279.
38. Taylor PD, Oon BB, Thomas CR, Poston L: Prevention by insulin treatment of endothelial dysfunction but not enhanced noradrenaline-induced contractility in mesenteric resistance arteries from streptozotocin-induced diabetic rats. Br J Pharmacol 1994;111:35-41.
39. Moore RD: Effects of insulin upon ion transport. Biochim Biophys Acta 1983;737:1-49.
40. Endothelins (editorial), Lancet 1991;i:79-81.
41. Lüscher TF, Seo B, Bühler FR: Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension 1993; 21(6 pt 1):752-757.
42. Vanhoutte PM: Is endothelin involved in the pathogenesis of hypertension? Hypertension 1993;21:747-751.
43. Schiffrin EL, Deng LY, Sventek P, Day R: Enhanced expression of endothelin-1 gene in severe human essential hypertension. J Hypertens 1997;15:57-63.
44. Sventek P, Li JS, Grove K, Deschepper CF, Schiffrin EL: Vascular structure and expression of endothelin-1 gene in L-NAME-treated spontaneously hypertensive rats. Hypertension 1996;27:49-55.
45. Webb DJ: Endogenous endothelin generation maintains vascular tone in humans. J Hum Hypertens 1995;9:459-463.
46. Lever AF: Slow pressor mechanisms in hypertension: A role for hypertrophy of resistance vessels? J Hypertens 1986;4:515-524.
47. Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, Agabiti Rosei E: Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;32:798-806.